Evaluation of hypersensitivity to microencapsulated ampicillin in guinea pigs.
The purpose of this study was to determine if the sustained release of ampicillin from a biodegradable drug-delivery system (microencapsulated ampicillin anhydrate (MEAA)) will increase or decrease the intensity of a hypersensitivity reaction compared with that observed with free drug. Ovalbumin, which is known to elicit a marked hypersensitivity reaction in guinea pigs, and microencapsulated ovalbumin (MOVA) were tested in parallel with ampicillin and MEAA. Guinea pigs were sensitized biweekly by subcutaneous and intramuscular injections of ampicillin, MEAA, ovalbumin, MOVA or placebo microspheres (test articles), each mixed with Freund's adjuvant, and challenged 2 weeks later, intradermally, with the free compounds. In a separate set of experiments, guinea pigs were sensitized by implantation of the same agents in the caudal thigh of anaesthetized animals. Skin allergic reactions were tested at 1 and 3 weeks following local implantation of the test articles. Sera of sensitized guinea pigs were tested for specific IgG antibodies by enzyme-linked immunosorbent assay, and skin samples from the site of the inflammatory reaction were fixed, stained and evaluated histologically. Guinea pigs sensitized systemically with MEAA or MOVA showed smaller, but not statistically different skin allergic response than animals given corresponding free compounds. However, guinea pigs sensitized by local implantation of MEAA showed a significantly lower inflammatory response (P < 0.0001) than those given an equivalent dose of the free drug. Guinea pigs sensitized with placebo microspheres showed a low inflammatory skin reaction which was similar to those sensitized with all doses of MEAA. There was no significant difference in specific IgG antibody response in the sera of guinea pigs sensitized locally with either free or microencapsulated ampicillin or ovalbumin. Histology of skin revealed a milder inflammatory reaction with MEAA or MOVA than with ampicillin or ovalbumin, respectively. We conclude that the encapsulated ampicillin or ovalbumin and subsequent release of each agent will elicit a reduced hypersensitivity reaction in guinea pigs than will the free agent.
Barsoum
I S
IS
US Army Dental Research Detachment, Walter Reed Army Institute of Research, Washington, DC 20307-5300, USA.
Kopydlowski
K M
KM
Cuenin
P
P
Setterstrom
J A
JA
D000667:Ampicillin / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D000818:Animals; D019072:Antibiotic Prophylaxis; D000906:Antibodies / Q000032:analysis; D000918:Antibody Specificity; D002214:Capsules; D004342:Drug Hypersensitivity / Q000276:immunology*; D004343:Drug Implants; D005260:Female; D006168:Guinea Pigs; D007249:Inflammation / Q000473:pathology; D008297:Male; D010047:Ovalbumin / Q000276:immunology; D010406:Penicillins / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology
D000906:Antibodies; D002214:Capsules; D004343:Drug Implants; D010406:Penicillins; D000667:Ampicillin; D010047:Ovalbumin